This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

Stocks in this article: JNJ F GSK HGSI

NEW YORK ( TheStreet) -- Popular searches on the Internet Thursday include Synthes after the European Union approved Johnson & Johnson's (JNJ) $21.3 billion acquisition of the Swiss orthopedics maker.

The EU said J&J's planned sale of its trauma business would ensure the combined companies would continue to face competition and leave enough alternatives for doctors and patients.

Synthes is J&J's largest acquisition to date. U.S. regulators have not yet approved the deal.

J&J offered to buy Synthes in April 2011 for 159 Swiss francs a share in cash and stock. It plans to sell its global trauma business to Biomet for $280 million in cash.

Ford (F) is trending as the automaker is planning a new $760 million assembly plant in China that is expected to double its output in the country.

Construction on the plant will start later this year and should open in 2015. Though it will initially produce 250,000 vehicles a year, Ford expects the plant to eventually double its production to 1.2 million vehicles annually.

The factory makes Ford's total investment in China now $4.9 billion. The company plans to bring 15 new models and 20 new engines and transmissions to the country by 2015.

Human Genome Sciences (HGSI) is another popular topic after rejecting an unsolicited $2.6 billion bid from GlaxoSmithKline (GSK). Human Genome said the $13-a-share cash offer "does not reflect the value inherent" in the company.

Human Genome said its board has authorized exploring strategic alternatives, include a possible sale of the company, and GlaxoSmithKline has been invited to participate in the process.

The two companies are partners on lupus treatment Benlysta, which was approved by U.S. and European regulators last year. The companies are also collaborating on two other experimental drugs.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs